Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 14Leukemia, Myelomonocytic, Chronic 3Myelodysplastic Syndromes 2Leukemia 2Sinonasal undifferentiated carcinoma 1Neoplasms 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Esthesioneuroblastoma, Olfactory 1Clonal Cytopenia of Undetermined Significance 1Chondrosarcoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1enasidenib 1Tomography, X-Ray Computed 1Radionuclide Imaging 1Positron-Emission Tomography 1Ibuprofen 1Electrocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esthesioneuroblastoma, Olfactory × enasidenib × 1 year × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡